Literature DB >> 27916680

The role of microRNAs in heart failure.

Hongjiang Wang1, Jun Cai2.   

Abstract

MicroRNAs are small non-coding RNA molecules that regulate gene expression by inhibiting mRNA translation and/or inducing mRNA degradation. In the past decade, many in vitro and in vivo studies have explored the involvement of microRNAs in various cardiovascular diseases. In this paper, studies focused upon the target genes and functionality of miRNAs in the pathophysiological processes of heart failure are reviewed. The selected miRNAs are categorized according to the biological relevance of their target genes in relation to four cardiovascular pathologies, namely angiogenesis, cardiac hypertrophy, fibrosis and apoptosis. This review illustrates the involvement of miRNAs in different biological signaling pathways and provides an overview of current understanding of the roles of miRNAs in cardiovascular health and diseases. This article is part of a Special Issue entitled: Genetic and epigenetic control of heart failure - edited by Jun Ren & Megan Yingmei Zhang.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  Angiogenesis; Apoptosis; Fibrosis; Heart failure; Hypertrophy; MicroRNA

Mesh:

Substances:

Year:  2016        PMID: 27916680     DOI: 10.1016/j.bbadis.2016.11.034

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  26 in total

1.  Attenuated macrophage activation mediated by microRNA-183 knockdown through targeting NR4A2.

Authors:  Fu-Han Gong; Li Long; Yong-Sheng Yang; De-Hong Shen; Yu-Song Zhang; Xue-Sheng Wang; Xue-Ping Zhang; Xiao-Qiang Xiao
Journal:  Exp Ther Med       Date:  2021-01-29       Impact factor: 2.447

Review 2.  Emerging role of angiogenesis in adaptive and maladaptive right ventricular remodeling in pulmonary hypertension.

Authors:  Andrea L Frump; Sébastien Bonnet; Vinicio A de Jesus Perez; Tim Lahm
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-11-02       Impact factor: 5.464

3.  Serum miRNAs are differentially altered by ethanol and caffeine consumption in rats.

Authors:  M Martinez; I M U Rossetto; R M S Arantes; F S N Lizarte; L F Tirapelli; D P C Tirapelli; L G A Chuffa; F E Martinez
Journal:  Toxicol Res (Camb)       Date:  2019-07-17       Impact factor: 3.524

Review 4.  MicroRNA-based therapeutics in central nervous system injuries.

Authors:  Ping Sun; Da Zhi Liu; Glen C Jickling; Frank R Sharp; Ke-Jie Yin
Journal:  J Cereb Blood Flow Metab       Date:  2018-04-30       Impact factor: 6.200

5.  MiR-221-3p targets Hif-1α to inhibit angiogenesis in heart failure.

Authors:  Yuying Li; Chenghui Yan; Jiahui Fan; Zhiwei Hou; Yaling Han
Journal:  Lab Invest       Date:  2020-09-01       Impact factor: 5.662

Review 6.  Salvia miltiorrhizaBurge (Danshen): a golden herbal medicine in cardiovascular therapeutics.

Authors:  Zhuo-Ming Li; Suo-Wen Xu; Pei-Qing Liu
Journal:  Acta Pharmacol Sin       Date:  2018-04-26       Impact factor: 6.150

Review 7.  MicroRNAs as monitoring markers for right-sided heart failure and congestive hepatopathy.

Authors:  Ruxandra Florentina Ionescu; Sanda Maria Cretoiu
Journal:  J Med Life       Date:  2021 Mar-Apr

Review 8.  CVD and COVID-19: Emerging Roles of Cardiac Fibroblasts and Myofibroblasts.

Authors:  Laxmansa C Katwa; Chelsea Mendoza; Madison Clements
Journal:  Cells       Date:  2022-04-13       Impact factor: 7.666

Review 9.  EndMT Regulation by Small RNAs in Diabetes-Associated Fibrotic Conditions: Potential Link With Oxidative Stress.

Authors:  Roberta Giordo; Yusra M A Ahmed; Hilda Allam; Salah Abusnana; Lucia Pappalardo; Gheyath K Nasrallah; Arduino Aleksander Mangoni; Gianfranco Pintus
Journal:  Front Cell Dev Biol       Date:  2021-05-19

Review 10.  The Role of Hydrogen Sulfide on Cardiovascular Homeostasis: An Overview with Update on Immunomodulation.

Authors:  Li-Long Pan; Ming Qin; Xin-Hua Liu; Yi-Zhun Zhu
Journal:  Front Pharmacol       Date:  2017-09-26       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.